US EditionPublished • loading... • Updated
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
Summary by The AI Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sciwind Biosciences Announces Ecnoglutide Injection Approved by China's National Medical Products Administration (NMPA) for Chronic Weight Management
HANGZHOU, China, March 6, 2026 /PRNewswire/ — Hangzhou Sciwind Biosciences Co., Ltd. (“Sciwind”), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China’s National Medical Products Administration (NMPA) has approved Ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. Ecnoglutide injection is the world’s first app…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
